Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Iniezione Intravitreale senza Speculum Utilizzando la Retrazione con Applicatore a Punta di Cotone: Uno Studio Randomizzato su Dolore, Tempo di Procedura, Soddisfazione del Paziente e Sicurezza (IVI-RETRACT)

22 settembre 2026 aggiornato da: Jakkrit Juhong

Iniezione Intravitreale Senza Speculum Mediante Retrazione con Applicatore a Punta di Cotone: Uno Studio Controllato Randomizzato che Confronta la Percezione del Dolore, la Durata della Procedura, la Soddisfazione del Paziente e la Sicurezza tra le Tecniche di Retrazione con Speculum Palpebrale e Applicatore a Punta di Cotone

This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI): an adjustable solid-blade eyelid speculum (Group A) and single-hand retraction of the upper eyelid with one cotton-tipped applicator (Group B), in patients with neovascular age-related macular degeneration (including polypoidal choroidal vasculopathy), diabetic macular edema, or retinal vein occlusion treated at Walailak University Hospital, Nakhon Si Thammarat, Thailand.

The study evaluates four outcomes: (1) pain on a 0-10 numbered pain scale with a faces pictogram, 1-5 minutes after injection; (2) procedure duration from the first contact of the retraction device with the eyelid to its removal; (3) patient satisfaction on a 5-item Likert questionnaire; and (4) safety, including subconjunctival hemorrhage, corneal abrasion, lens touch, vitreous hemorrhage, endophthalmitis, retinal detachment, and intraocular pressure elevation.

In both groups, the cap of the insulin syringe is used as an injection-site marker instead of a caliper. Randomization was stratified by diagnosis and prior injection history using permuted blocks of 4 and 6. All 129 participants were randomized and injected on September 9, 2026.

Panoramica dello studio

Descrizione dettagliata

Background:

Intravitreal injection is one of the most frequently performed ophthalmic procedures. Eyelid specula are widely used to keep the eye open but may cause discomfort. Cotton-tipped applicator retraction is an alternative that may reduce pain, and when a single applicator is held in one hand, the other hand remains free for injection-site marking and injection, so that one surgeon can complete the procedure without an assistant. Randomized data on procedure duration and satisfaction are limited.

Study Design:

Single-center, prospective, parallel-group randomized controlled trial with 1:1 allocation to an eyelid speculum (Group A) or cotton-tipped applicator retraction (Group B). The principal investigator generated stratified permuted-block sequences (block sizes 4 and 6) with Study Randomizer software; there were six strata: diagnosis (nAMD / DME / RVO) x prior injection history (injection-naive / previously injected). A research assistant placed the assignments in sequentially numbered, opaque, sealed envelopes, which another research assistant opened immediately before each procedure.

Interventions:

One vitreoretinal surgeon performed all injections without an assistant. Injections were given in the superotemporal quadrant in right eyes and the superonasal quadrant in left eyes (surgeon preference, same in both groups). All participants received tetracaine 0.5% and povidone-iodine 5% drops in the waiting area (contact time of at least 5 minutes), povidone-iodine 10% periocular skin preparation, a second instillation of tetracaine, and a fenestrated cloth drape. Anti-VEGF agents (bevacizumab, aflibercept, or faricimab) were prepared by the hospital pharmacy in 1-mL insulin syringes with a fixed 31G needle (Terumo). Group A: adjustable solid-blade eyelid speculum with a screw lock (PMS) retracting the upper and lower eyelids. Group B: one sterile cotton-tipped applicator held in the left hand to retract the upper eyelid; conversion to the speculum if retraction failed after 2 attempts. If the first attempt failed because of forceful eyelid squeezing or a marked Bell phenomenon, the participant was asked to close the eye, the applicator was used to retract the lower eyelid, and the injection was given in the inferotemporal or inferonasal quadrant. The injection site was marked with the povidone-iodine-dipped cap of the insulin syringe. Levofloxacin 0.5% was instilled after injection.

Outcome Measures:

All four outcomes are primary. Pain (0-10 numbered pain scale with faces), procedure duration (seconds), and satisfaction (5-item Likert questionnaire, total 5-25) were assessed on Day 0, 1-5 minutes after injection. Safety outcomes were assessed on Day 0, Day 1 (telephone), and Week 4 (clinic visit). Pain, procedure duration, and satisfaction are tested at a Bonferroni-adjusted alpha of 0.0167; safety is summarized descriptively (statistical analysis plan version 1.0, locked September 21, 2026).

Masking:

Open label. Participants, the surgeon, and the research assistants who timed the procedure and assessed the outcomes were aware of group assignment.

Sample Size:

Based on Chen et al. (2025) (pooled SD 1.71 for pain; Cohen's d = 0.57), with alpha = 0.025 (Bonferroni correction for 2 outcomes) and 80% power, 60 patients per group are required for pain (the earlier version of this record reported 52 per group because of a calculation error) and 46 per group for procedure duration. The enrollment target was 60 per group (120 total). All eligible patients who attended the injection session and gave consent were randomized (actual enrollment, 129).

Tipo di studio

Interventistico

Iscrizione (Effettivo)

129

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Changwat Nakhon Si Thammarat
      • Tha Sala, Changwat Nakhon Si Thammarat, Tailandia, 80160
        • Walailak University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age 18 years or older
  2. Diagnosed with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion (RVO)
  3. Scheduled for intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab)
  4. Able to provide written informed consent

Exclusion Criteria:

  1. Active ocular infection or inflammation
  2. Known allergy to povidone-iodine, tetracaine, or levofloxacin
  3. Inability to cooperate with the injection procedure
  4. Concurrent participation in another interventional clinical trial
  5. Anatomical eyelid abnormality precluding use of either retraction technique

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Eyelid Speculum (Group A)

Intravitreal injection performed with an adjustable solid-blade eyelid speculum with a screw lock (PMS) retracting the upper and lower eyelids. The speculum is inserted immediately before injection-site marking and injection and removed immediately after needle withdrawal.

An adjustable solid-blade eyelid speculum with a screw lock (PMS) is inserted to retract the upper and lower eyelids before intravitreal injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). The speculum is removed immediately after needle withdrawal.

Sperimentale: Cotton-Tipped Applicator (Group B)

A single sterile cotton-tipped applicator, held in the surgeon's left hand, retracts the upper eyelid (speculum-free) before intravitreal injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). If the first attempt fails because of forceful eyelid squeezing or a marked Bell phenomenon, the participant is asked to close the eye, the applicator is used to retract the lower eyelid, and the injection is given in the inferotemporal or inferonasal quadrant. The eyelid speculum is used if retraction fails after 2 attempts. The applicator is removed immediately after needle withdrawal.

One sterile cotton-tipped applicator, held in the surgeon's left hand, is used to retract the upper eyelid (speculum-free) before intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). The right hand marks the injection site and injects. If the first attempt fails because of forceful eyelid squeezing or a marked Bell phenomenon, the participant is asked to close the eye, the applicator is used to retract the lower eyelid, and the injection is given in the inferotemporal or inferonasal quadrant. The eyelid speculum is used if retraction fails after 2 attempts. The applicator is removed immediately after needle withdrawal.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain Perception
Lasso di tempo: 1-5 minutes after intravitreal injection (Day 0)

Patient-reported pain score on a 0-10 numbered pain scale with a faces pictogram and verbal categories (0 = no pain; 10 = worst pain). The participant pointed to or stated a level, and a research assistant recorded the score after the participant had left the injection room.

1-5 minutes after intravitreal injection (Day 0)
Procedure Duration
Lasso di tempo: During intravitreal injection procedure (Day 0)

Time in seconds from the first contact of the retraction device (speculum or cotton-tipped applicator) with the eyelid to its complete removal after needle withdrawal, measured by a research assistant with a stopwatch.

During intravitreal injection procedure (Day 0)
Patient Satisfaction
Lasso di tempo: 1-5 minutes after intravitreal injection (Day 0)

Total score on a 5-item Likert satisfaction questionnaire in Thai (item 3, squeezing or pressure on the eyelid, reverse-scored; total 5-25; higher scores indicate greater satisfaction), administered at the same assessment as the pain score.

1-5 minutes after intravitreal injection (Day 0)
Procedure-Related Complications
Lasso di tempo: Day 0, Day 1, and Week 4 post-injection

Incidence of ocular complications, including subconjunctival hemorrhage, corneal abrasion, lens touch, vitreous hemorrhage, endophthalmitis, rhegmatogenous retinal detachment, and intraocular pressure greater than 25 mmHg, assessed on Day 0 (clinic), Day 1 (telephone call), and Week 4 (clinic visit).

Day 0, Day 1, and Week 4 post-injection

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Jakkrit Juhong, MD, Walailak University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 settembre 2026

Completamento primario (Stimato)

7 ottobre 2026

Completamento dello studio (Stimato)

7 ottobre 2026

Date di iscrizione allo studio

Primo inviato

13 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 marzo 2026

Primo Inserito (Effettivo)

18 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data underlying the results reported in the article (baseline characteristics, pain, procedure duration, satisfaction, and adverse events), with a data dictionary, will be shared on reasonable request to the principal investigator.

Periodo di condivisione IPD

Beginning after publication of the primary results and for at least 5 years thereafter.

Criteri di accesso alla condivisione IPD

Qualified researchers who submit a methodologically sound proposal to the principal investigator (jakkrit.ju@wu.ac.th). Data will be shared after approval of the proposal and signature of a data use agreement, in accordance with the requirements of the Ethics Committee in Human Research, Walailak University.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi